Included in the collaboration are formulations for therapeutics directed at the human neonatal Fc receptor (FcRn), including efgartigimod and up to one additional target, according to a news release. The formulations are designed to promote additional optionality for patients through at-home and self-administration capabilities, Elektrofi said.
Boston-based Elektrofi will receive an upfront payment and future milestone payments across both targets from Argenx, pending achievement of pre-defined development, regulatory and commercial milestones.
Elektrofi will also receive a mid-single-digit royalty on sales of commercialized products under the terms of the agreement with Argenx.
“Our agreement with argenx is another strong indicator of industry interest in our technology, the benefit of at-home and self-administration options, and our universal commitment to optimizing the patient experience,” Elektrofi co-founder & CEO Chase Coffman said in the release. “We are excited to be working closely with the Argenx team to develop product candidates that may address severe and debilitating diseases.”